Eli Lilly is stockpiling $1.5 billion worth of orforgliprone ahead of launch to avoid shortages of GLP-1RA drugs.[1] This stock represents an increase from last year, when the company reported $550 million in pre-launch.[1] The goal is to ensure sufficient supply at launch and quickly gain a foothold in the competitive obesity drug market.[1] Orforglipron is an experimental oral weight loss drug that has been granted expedited processing by the FDA.[1][2] An FDA approval decision is expected in the second quarter of 2026, with a target date of April 10, 2026.[2][4] The company uses a national priority voucher to speed up the review.[2][4] In a clinical trial, patients who switched from injectable drugs like Wegovy or Zepbound to orforglipron maintained 95% or 80% of their lost weight after 52 weeks.[3]